<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00464945</url>
  </required_header>
  <id_info>
    <org_study_id>6096A1-3000</org_study_id>
    <nct_id>NCT00464945</nct_id>
  </id_info>
  <brief_title>Wyeth Study To Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants</brief_title>
  <official_title>A Phase 3, Randomised,Active-Controlled ,Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Manufacturing Scale 13-valent Pneumococcal Conjugate Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability and immunogenicity of
      manufacturing scale 13-valent pneumococcal conjugate (13vPnC) vaccine compared to pilot scale
      13vPnC in healthy infants when given with routine pediatric vaccines.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Antibody Level ≥0.35μg/mL in 13vPnC Manufacturing Scale Group Relative to 13vPnC Pilot Scale Group After the 3-Dose Infant Series</measure>
    <time_frame>One month after 3-dose infant series (5 months of age)</time_frame>
    <description>Percentages of participants achieving WHO predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Pre-Specified Local Reactions</measure>
    <time_frame>During the 4-day period after each dose</time_frame>
    <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant(Sig) (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (Mod) (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Participants may be represented in more than 1 category.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Pre-Specified Systemic Events (Infant Series)</measure>
    <time_frame>During the 4-day period after each dose</time_frame>
    <description>Systemic events (fever ≥ 38 degrees Celsius [C] but ≤ 39 C, fever &gt;39 C but ≤ 40 C, fever &gt; 40 C, decreased appetite, irritability, increased sleep, decreased sleep, use of medication (Meds)to prevent symptoms (sx), and use of medication to treat symptoms) were collected using an electronic diary. Participants may be represented in more than 1 category.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Pre-Specified Systemic Events (Toddler Series)</measure>
    <time_frame>During the 4-day period after toddler dose</time_frame>
    <description>Systemic events (fever ≥ 38 degrees Celsius [C] but ≤ 39 C, fever &gt;39 C but ≤ 40 C, fever &gt; 40 C), decreased appetite, irritability, increased sleep, decreased sleep, use of medication to prevent symptoms, and use of medication to treat symptoms) were collected using an electronic diary. Participants may be represented in more than 1 category.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Antibody Concentration in 13vPnC Manufacturing Scale Group Relative to 13vPnC Pilot Scale Group After the 3-Dose Infant Series</measure>
    <time_frame>One month after 3-dose infant series (5 months of age)</time_frame>
    <description>Antibody concentration/geometric mean concentration (GMC) as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">269</enrollment>
  <condition>Pneumococcal Vaccines</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13-valent Pneumococcal Conjugate Vaccine</intervention_name>
    <description>1 dose at 2,3,4 and 12 months of age</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Aged 2 months (42 to 98 days) at time of enrollment.

          2. Available for entire study period and whose parent/legal guardian can be reached by
             telephone.

          3. Healthy infant as determined by medical history, physical examination, and judgment of
             the investigator.

          4. Parent/legal guardian must be able to complete all relevant study procedures during
             study participation.

        Exclusion criteria:

          1. Previous vaccination with licensed or investigational pneumococcal, Hib conjugate,
             diphtheria, tetanus, pertussis, or polio vaccines.

          2. A previous anaphylactic reaction to any vaccine or vaccine-related component.

          3. Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis,
             polio, hepatitis B, measles, mumps, rubella, or pneumococcal vaccines.

          4. Bleeding diathesis or condition associated with prolonged bleeding time that would
             contraindicate intramuscular injection.

          5. Known or suspected immune deficiency or suppression.

          6. History of culture-proven invasive disease caused by S pneumoniae.

          7. Major known congenital malformation or serious chronic disorders.

          8. Significant neurological disorder or history of seizure including febrile seizure, or
             significant stable or evolving disorders such as cerebral palsy, encephalopathy,
             hydrocephalus, or other significant disorders. Does not include resolving syndromes
             due to birth trauma such as Erb palsy.

          9. Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and
             monoclonal antibodies; eg, Synagis®).

         10. Participation in another investigational or interventional trial. Participation in
             purely observational studies is acceptable.

         11. Infant who is a direct descendant (child or grandchild) of a member of the study site
             personnel.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>41 Days</minimum_age>
    <maximum_age>99 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Trial Manager</last_name>
    <role>Principal Investigator</role>
    <affiliation>For Poland, WPWZMED@wyeth.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Torun</city>
        <state>Bydgoszcz</state>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Siemianowice Slaskie</city>
        <state>Krakow</state>
        <zip>41-103</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lubartowie</city>
        <state>Lublin</state>
        <zip>21-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <zip>30-663</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <zip>31-442</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <zip>91-347</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <zip>93-338</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <zip>20-044</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <zip>01-184</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2007</study_first_submitted>
  <study_first_submitted_qc>April 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2007</study_first_posted>
  <results_first_submitted>March 26, 2010</results_first_submitted>
  <results_first_submitted_qc>July 6, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 15, 2012</results_first_posted>
  <disposition_first_submitted>February 26, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>September 30, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 1, 2009</disposition_first_posted>
  <last_update_submitted>July 6, 2012</last_update_submitted>
  <last_update_submitted_qc>July 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited in Poland from June 2007 to August 2007.</recruitment_details>
      <pre_assignment_details>Participants were enrolled into the study according to inclusion/exclusion criteria without a screening period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>13vPnC Manufacturing</title>
          <description>Participants received one single 0.5mL manufacturing scale dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with combined diphtheria, tetanus, and acellular pertussis inactivated poliovirus, and hemophilus influenza type b vaccine (DTaP-IPV-Hib) and hepatitis B virus vaccine (HBV) at 2 months (infant series, dose 1). Participants received one single 0.5mL manufacturing scale dose of 13vPnC coadministered with DTaP-IPV-Hib at 3 and 4 months (infant series, dose 2 and 3). Participants received one single 0.5mL manufacturing scale dose of 13vPnC coadministered with measles, mumps, and rubella vaccine (MMR) and 12 months of age (toddler dose).</description>
        </group>
        <group group_id="P2">
          <title>13vPnC Pilot</title>
          <description>Participants received one single 0.5mL pilot scale dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with combined diphtheria, tetanus, and acellular pertussis inactivated poliovirus, and hemophilus influenza type b vaccine (DTaP-IPV-Hib) and hepatitis B virus vaccine (HBV) at 2 months (infant series, dose 1). Participants received one single 0.5mL pilot scale dose of 13vPnC coadministered with DTaP-IPV-Hib at 3 and 4 months (infant series, dose 2 and 3). Participants received one single 0.5mL pilot scale dose of 13vPnC coadministered with measles, mumps, and rubella vaccine (MMR) and 12 months of age (toddler dose).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Infant Series</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="135"/>
                <participants group_id="P2" count="134"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 1</title>
              <participants_list>
                <participants group_id="P1" count="134"/>
                <participants group_id="P2" count="134"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 2</title>
              <participants_list>
                <participants group_id="P1" count="132"/>
                <participants group_id="P2" count="133"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 3</title>
              <participants_list>
                <participants group_id="P1" count="132"/>
                <participants group_id="P2" count="133"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="131"/>
                <participants group_id="P2" count="133"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by parent/guardian request</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>After Infant Series</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="131"/>
                <participants group_id="P2" count="133"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="131"/>
                <participants group_id="P2" count="131"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Toddler Dose</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="131"/>
                <participants group_id="P2" count="131"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="131"/>
                <participants group_id="P2" count="130"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>13vPnC Manufacturing</title>
          <description>Participants received one single 0.5mL manufacturing scale dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with combined diphtheria, tetanus, and acellular pertussis inactivated poliovirus, and hemophilus influenza type b vaccine (DTaP-IPV-Hib) and hepatitis B virus vaccine (HBV) at 2 months (infant series, dose 1). Participants received one single 0.5mL manufacturing scale dose of 13vPnC coadministered with DTaP-IPV-Hib at 3 and 4 months (infant series, dose 2 and 3). Participants received one single 0.5mL manufacturing scale dose of 13vPnC coadministered with measles, mumps, and rubella vaccine (MMR) and 12 months of age (toddler dose).</description>
        </group>
        <group group_id="B2">
          <title>13vPnC Pilot</title>
          <description>Participants received one single 0.5mL pilot scale dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with combined diphtheria, tetanus, and acellular pertussis inactivated poliovirus, and hemophilus influenza type b vaccine (DTaP-IPV-Hib) and hepatitis B virus vaccine (HBV) at 2 months (infant series, dose 1). Participants received one single 0.5mL pilot scale dose of 13vPnC coadministered with DTaP-IPV-Hib at 3 and 4 months (infant series, dose 2 and 3). Participants received one single 0.5mL pilot scale dose of 13vPnC coadministered with measles, mumps, and rubella vaccine (MMR) and 12 months of age (toddler dose).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="135"/>
            <count group_id="B2" value="134"/>
            <count group_id="B3" value="269"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.1" spread="0.6"/>
                    <measurement group_id="B2" value="2.1" spread="0.5"/>
                    <measurement group_id="B3" value="2.1" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Antibody Level ≥0.35μg/mL in 13vPnC Manufacturing Scale Group Relative to 13vPnC Pilot Scale Group After the 3-Dose Infant Series</title>
        <description>Percentages of participants achieving WHO predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
        <time_frame>One month after 3-dose infant series (5 months of age)</time_frame>
        <population>Evaluable immunogenicity (per protocol) population consisting of eligible participants who adhered to protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Manufacturing</title>
            <description>Participants received one single 0.5mL manufacturing scale dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with combined diphtheria, tetanus, and acellular pertussis inactivated poliovirus, and hemophilus influenza type b vaccine (DTaP-IPV-Hib) and hepatitis B virus vaccine (HBV) at 2 months (infant series, dose 1). Participants received one single 0.5mL manufacturing scale dose of 13vPnC coadministered with DTaP-IPV-Hib at 3 and 4 months (infant series, dose 2 and 3). Participants received one single 0.5mL manufacturing scale dose of 13vPnC coadministered with measles, mumps, and rubella vaccine (MMR) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Pilot</title>
            <description>Participants received one single 0.5mL pilot scale dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with combined diphtheria, tetanus, and acellular pertussis inactivated poliovirus, and hemophilus influenza type b vaccine (DTaP-IPV-Hib) and hepatitis B virus vaccine (HBV) at 2 months (infant series, dose 1). Participants received one single 0.5mL pilot scale dose of 13vPnC coadministered with DTaP-IPV-Hib at 3 and 4 months (infant series, dose 2 and 3). Participants received one single 0.5mL pilot scale dose of 13vPnC coadministered with measles, mumps, and rubella vaccine (MMR) and 12 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Antibody Level ≥0.35μg/mL in 13vPnC Manufacturing Scale Group Relative to 13vPnC Pilot Scale Group After the 3-Dose Infant Series</title>
          <description>Percentages of participants achieving WHO predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
          <population>Evaluable immunogenicity (per protocol) population consisting of eligible participants who adhered to protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common Serotypes-Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.7" lower_limit="93.3" upper_limit="99.5"/>
                    <measurement group_id="O2" value="96.9" lower_limit="92.4" upper_limit="99.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes-Serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.3" lower_limit="69.1" upper_limit="84.3"/>
                    <measurement group_id="O2" value="74.0" lower_limit="65.7" upper_limit="81.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes-Serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.4" lower_limit="94.5" upper_limit="99.8"/>
                    <measurement group_id="O2" value="96.2" lower_limit="91.3" upper_limit="98.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes-Serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.9" lower_limit="87.0" upper_limit="96.7"/>
                    <measurement group_id="O2" value="94.5" lower_limit="89.1" upper_limit="97.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes-Serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.1" lower_limit="91.1" upper_limit="98.7"/>
                    <measurement group_id="O2" value="93.1" lower_limit="87.4" upper_limit="96.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes-Serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.4" lower_limit="94.4" upper_limit="99.8"/>
                    <measurement group_id="O2" value="97.7" lower_limit="93.5" upper_limit="99.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes-Serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.8" lower_limit="75.1" upper_limit="88.9"/>
                    <measurement group_id="O2" value="81.7" lower_limit="74.0" upper_limit="87.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes-Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.0" lower_limit="87.1" upper_limit="96.7"/>
                    <measurement group_id="O2" value="90.8" lower_limit="84.5" upper_limit="95.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes-Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.7" lower_limit="88.0" upper_limit="97.2"/>
                    <measurement group_id="O2" value="95.4" lower_limit="90.3" upper_limit="98.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes-Serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.6" lower_limit="84.2" upper_limit="95.1"/>
                    <measurement group_id="O2" value="88.5" lower_limit="81.8" upper_limit="93.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes-Serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.2" lower_limit="77.8" upper_limit="90.8"/>
                    <measurement group_id="O2" value="86.3" lower_limit="79.2" upper_limit="91.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes-Serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="97.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes-Serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.2" lower_limit="95.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.2" lower_limit="95.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 4 the difference in percentages between the two groups (13vPnC Manufacturing - 13vPnC Pilot) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.9</ci_lower_limit>
            <ci_upper_limit>5.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 6B the difference in percentages between the two groups (13vPnC Manufacturing - 13vPnC Pilot) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>3.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-7.3</ci_lower_limit>
            <ci_upper_limit>13.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 9V the difference in percentages between the two groups (13vPnC Manufacturing - 13vPnC Pilot) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.1</ci_lower_limit>
            <ci_upper_limit>7.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 14 the difference in percentages between the two groups (13vPnC Manufacturing - 13vPnC Pilot) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>-1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-8.2</ci_lower_limit>
            <ci_upper_limit>4.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 18C the difference in percentages between the two groups (13vPnC Manufacturing - 13vPnC Pilot) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>3.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.8</ci_lower_limit>
            <ci_upper_limit>9.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 19F the difference in percentages between the two groups (13vPnC Manufacturing - 13vPnC Pilot) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.5</ci_lower_limit>
            <ci_upper_limit>5.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 23F the difference in percentages between the two groups (13vPnC Manufacturing - 13vPnC Pilot) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-8.4</ci_lower_limit>
            <ci_upper_limit>10.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 1 the difference in percentages between the two groups (13vPnC Manufacturing - 13vPnC Pilot) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.8</ci_lower_limit>
            <ci_upper_limit>9.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 3 the difference in percentages between the two groups (13vPnC Manufacturing - 13vPnC Pilot) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>-1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-7.9</ci_lower_limit>
            <ci_upper_limit>4.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 5 the difference in percentages between the two groups (13vPnC Manufacturing - 13vPnC Pilot) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.6</ci_lower_limit>
            <ci_upper_limit>9.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 6A the difference in percentages between the two groups (13vPnC Manufacturing - 13vPnC Pilot) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>-1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-9.9</ci_lower_limit>
            <ci_upper_limit>7.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 7F the difference in percentages between the two groups (13vPnC Manufacturing - 13vPnC Pilot) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.0</ci_lower_limit>
            <ci_upper_limit>2.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 19A the difference in percentages between the two groups (13vPnC Manufacturing - 13vPnC Pilot) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>-0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.6</ci_lower_limit>
            <ci_upper_limit>3.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting Pre-Specified Local Reactions</title>
        <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant(Sig) (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (Mod) (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Participants may be represented in more than 1 category.</description>
        <time_frame>During the 4-day period after each dose</time_frame>
        <population>The safety population included all participants who received at least 1 dose of vaccine; (n) = number of participants reporting yes for at least 1 day or no for all days.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Manufacturing Dose 1</title>
            <description>Participants received one single 0.5mL manufacturing scale dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with combined diphtheria, tetanus, and acellular pertussis inactivated poliovirus, and hemophilus influenza type b vaccine (DTaP-IPV-Hib) and hepatitis B virus vaccine (HBV) at 2 months (infant series, dose 1).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Pilot Dose 1</title>
            <description>Participants received one single 0.5mL pilot scale dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with combined diphtheria, tetanus, and acellular pertussis inactivated poliovirus, and hemophilus influenza type b vaccine (DTaP-IPV-Hib) and hepatitis B virus vaccine (HBV) at 2 months (infant series, dose 1).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC Manufacturing Dose 2</title>
            <description>Participants received one single 0.5mL manufacturing scale dose of 13vPnC coadministered with DTaP-IPV-Hib at 3 and 4 months (infant series, dose 2 and 3).</description>
          </group>
          <group group_id="O4">
            <title>13vPnC Pilot Dose 2</title>
            <description>Participants received one single 0.5mL pilot scale dose of 13vPnC coadministered with DTaP-IPV-Hib at 3 and 4 months (infant series, dose 2 and 3).</description>
          </group>
          <group group_id="O5">
            <title>13vPnC Manufacturing Dose 3</title>
            <description>Participants received one single 0.5mL manufacturing scale dose of 13vPnC coadministered with DTaP-IPV-Hib at 3 and 4 months (infant series, dose 2 and 3).</description>
          </group>
          <group group_id="O6">
            <title>13vPnC Pilot Dose 3</title>
            <description>Participants received one single 0.5mL pilot scale dose of 13vPnC coadministered with DTaP-IPV-Hib at 3 and 4 months (infant series, dose 2 and 3).</description>
          </group>
          <group group_id="O7">
            <title>13vPnC Manufacturing Toddler Dose</title>
            <description>Participants received one single 0.5mL manufacturing scale dose of 13vPnC coadministered with measles, mumps, and rubella vaccine (MMR) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O8">
            <title>13vPnC Pilot Toddler Dose</title>
            <description>Participants received one single 0.5mL pilot scale dose of 13vPnC coadministered with measles, mumps, and rubella vaccine (MMR) and 12 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-Specified Local Reactions</title>
          <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant(Sig) (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (Mod) (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Participants may be represented in more than 1 category.</description>
          <population>The safety population included all participants who received at least 1 dose of vaccine; (n) = number of participants reporting yes for at least 1 day or no for all days.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="133"/>
                <count group_id="O5" value="132"/>
                <count group_id="O6" value="133"/>
                <count group_id="O7" value="131"/>
                <count group_id="O8" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tenderness-Any (n=133,130,128,128,124,119,115,117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8"/>
                    <measurement group_id="O2" value="20.0"/>
                    <measurement group_id="O3" value="20.3"/>
                    <measurement group_id="O4" value="17.2"/>
                    <measurement group_id="O5" value="15.3"/>
                    <measurement group_id="O6" value="12.6"/>
                    <measurement group_id="O7" value="24.3"/>
                    <measurement group_id="O8" value="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness-Sig (n=131,129,128,128,124,119,112,114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="3.9"/>
                    <measurement group_id="O3" value="1.6"/>
                    <measurement group_id="O4" value="3.1"/>
                    <measurement group_id="O5" value="1.6"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="1.8"/>
                    <measurement group_id="O8" value="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling-Any (n=132,130,129,129,126,122,113,115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                    <measurement group_id="O2" value="20.0"/>
                    <measurement group_id="O3" value="30.2"/>
                    <measurement group_id="O4" value="27.1"/>
                    <measurement group_id="O5" value="29.4"/>
                    <measurement group_id="O6" value="30.3"/>
                    <measurement group_id="O7" value="22.1"/>
                    <measurement group_id="O8" value="26.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling-Mild (n=132,130,129,129,126,121,113,115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7"/>
                    <measurement group_id="O2" value="17.7"/>
                    <measurement group_id="O3" value="29.5"/>
                    <measurement group_id="O4" value="25.6"/>
                    <measurement group_id="O5" value="27.0"/>
                    <measurement group_id="O6" value="25.6"/>
                    <measurement group_id="O7" value="22.1"/>
                    <measurement group_id="O8" value="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling-Mod (n=132,129,128,128,124,120,113,114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1"/>
                    <measurement group_id="O2" value="7.0"/>
                    <measurement group_id="O3" value="8.6"/>
                    <measurement group_id="O4" value="8.6"/>
                    <measurement group_id="O5" value="8.9"/>
                    <measurement group_id="O6" value="13.3"/>
                    <measurement group_id="O7" value="8.8"/>
                    <measurement group_id="O8" value="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling-Severe(n=131,129,128,128,124,119,112,113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="0.0"/>
                    <measurement group_id="O8" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness-Any (n=132,131,129,131,125,123,115,116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.8"/>
                    <measurement group_id="O2" value="24.4"/>
                    <measurement group_id="O3" value="37.2"/>
                    <measurement group_id="O4" value="33.6"/>
                    <measurement group_id="O5" value="40.0"/>
                    <measurement group_id="O6" value="34.1"/>
                    <measurement group_id="O7" value="37.4"/>
                    <measurement group_id="O8" value="42.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness-Mild (n=132,131,129,131,125,123,115,115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.8"/>
                    <measurement group_id="O2" value="22.9"/>
                    <measurement group_id="O3" value="36.4"/>
                    <measurement group_id="O4" value="33.6"/>
                    <measurement group_id="O5" value="38.4"/>
                    <measurement group_id="O6" value="33.3"/>
                    <measurement group_id="O7" value="33.9"/>
                    <measurement group_id="O8" value="36.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness-Mod (n=131,129,128,128,124,119,113,114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="1.6"/>
                    <measurement group_id="O3" value="3.1"/>
                    <measurement group_id="O4" value="1.6"/>
                    <measurement group_id="O5" value="5.6"/>
                    <measurement group_id="O6" value="3.4"/>
                    <measurement group_id="O7" value="10.6"/>
                    <measurement group_id="O8" value="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness-Severe(n=131,129,128,128,124,119,112,113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="0.0"/>
                    <measurement group_id="O8" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting Pre-Specified Systemic Events (Infant Series)</title>
        <description>Systemic events (fever ≥ 38 degrees Celsius [C] but ≤ 39 C, fever &gt;39 C but ≤ 40 C, fever &gt; 40 C, decreased appetite, irritability, increased sleep, decreased sleep, use of medication (Meds)to prevent symptoms (sx), and use of medication to treat symptoms) were collected using an electronic diary. Participants may be represented in more than 1 category.</description>
        <time_frame>During the 4-day period after each dose</time_frame>
        <population>The safety population included all participants (268) who received at least 1 dose of vaccine; (n) = number of participants reporting yes for at least 1 day or no for all days.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Manufacturing Dose 1</title>
            <description>Participants received one single 0.5mL manufacturing scale dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with combined diphtheria, tetanus, and acellular pertussis inactivated poliovirus, and hemophilus influenza type b vaccine (DTaP-IPV-Hib) and hepatitis B virus vaccine (HBV) at 2 months (infant series, dose 1).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Pilot Dose 1</title>
            <description>Participants received one single 0.5mL pilot scale dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with combined diphtheria, tetanus, and acellular pertussis inactivated poliovirus, and hemophilus influenza type b vaccine (DTaP-IPV-Hib) and hepatitis B virus vaccine (HBV) at 2 months (infant series, dose 1).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC Manufacturing Dose 2</title>
            <description>Participants received one single 0.5mL manufacturing scale dose of 13vPnC coadministered with DTaP-IPV-Hib at 3 and 4 months (infant series, dose 2 and 3).</description>
          </group>
          <group group_id="O4">
            <title>13vPnC Pilot Dose 2</title>
            <description>Participants received one single 0.5mL pilot scale dose of 13vPnC coadministered with DTaP-IPV-Hib at 3 and 4 months (infant series, dose 2 and 3).</description>
          </group>
          <group group_id="O5">
            <title>13vPnC Manufacturing Dose 3</title>
            <description>Participants received one single 0.5mL manufacturing scale dose of 13vPnC coadministered with DTaP-IPV-Hib at 3 and 4 months (infant series, dose 2 and 3).</description>
          </group>
          <group group_id="O6">
            <title>13vPnC Pilot Dose 3</title>
            <description>Participants received one single 0.5mL pilot scale dose of 13vPnC coadministered with DTaP-IPV-Hib at 3 and 4 months (infant series, dose 2 and 3).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-Specified Systemic Events (Infant Series)</title>
          <description>Systemic events (fever ≥ 38 degrees Celsius [C] but ≤ 39 C, fever &gt;39 C but ≤ 40 C, fever &gt; 40 C, decreased appetite, irritability, increased sleep, decreased sleep, use of medication (Meds)to prevent symptoms (sx), and use of medication to treat symptoms) were collected using an electronic diary. Participants may be represented in more than 1 category.</description>
          <population>The safety population included all participants (268) who received at least 1 dose of vaccine; (n) = number of participants reporting yes for at least 1 day or no for all days.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="133"/>
                <count group_id="O5" value="132"/>
                <count group_id="O6" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever ≥38°C but ≤39°C (n=132,130,129,130,124,121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2"/>
                    <measurement group_id="O2" value="19.2"/>
                    <measurement group_id="O3" value="16.3"/>
                    <measurement group_id="O4" value="20.0"/>
                    <measurement group_id="O5" value="11.3"/>
                    <measurement group_id="O6" value="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;39°C but ≤40°C (n=131,129,128,128,124,119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0.8"/>
                    <measurement group_id="O3" value="0.8"/>
                    <measurement group_id="O4" value="1.6"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;40°C (n=131,129,128,128,124,119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite (n=133,129,129,128,125,121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.3"/>
                    <measurement group_id="O2" value="24.0"/>
                    <measurement group_id="O3" value="14.7"/>
                    <measurement group_id="O4" value="15.6"/>
                    <measurement group_id="O5" value="16.8"/>
                    <measurement group_id="O6" value="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (n=134,131,130,131,127,123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="51.9"/>
                    <measurement group_id="O3" value="53.8"/>
                    <measurement group_id="O4" value="49.6"/>
                    <measurement group_id="O5" value="41.7"/>
                    <measurement group_id="O6" value="37.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased sleep (n=132,129,128,129124,121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.7"/>
                    <measurement group_id="O2" value="39.5"/>
                    <measurement group_id="O3" value="25.0"/>
                    <measurement group_id="O4" value="29.5"/>
                    <measurement group_id="O5" value="20.2"/>
                    <measurement group_id="O6" value="30.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased sleep (n=132,130,129,129,124,123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3"/>
                    <measurement group_id="O2" value="32.3"/>
                    <measurement group_id="O3" value="24.0"/>
                    <measurement group_id="O4" value="20.9"/>
                    <measurement group_id="O5" value="18.5"/>
                    <measurement group_id="O6" value="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meds to treat sx (n=132,130,128,128,124,123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9"/>
                    <measurement group_id="O2" value="17.7"/>
                    <measurement group_id="O3" value="13.3"/>
                    <measurement group_id="O4" value="14.1"/>
                    <measurement group_id="O5" value="8.9"/>
                    <measurement group_id="O6" value="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meds to prevent sx (n=132,130,128,129124,121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9"/>
                    <measurement group_id="O2" value="9.2"/>
                    <measurement group_id="O3" value="11.7"/>
                    <measurement group_id="O4" value="10.1"/>
                    <measurement group_id="O5" value="10.5"/>
                    <measurement group_id="O6" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting Pre-Specified Systemic Events (Toddler Series)</title>
        <description>Systemic events (fever ≥ 38 degrees Celsius [C] but ≤ 39 C, fever &gt;39 C but ≤ 40 C, fever &gt; 40 C), decreased appetite, irritability, increased sleep, decreased sleep, use of medication to prevent symptoms, and use of medication to treat symptoms) were collected using an electronic diary. Participants may be represented in more than 1 category.</description>
        <time_frame>During the 4-day period after toddler dose</time_frame>
        <population>The safety population included all participants who received at least 1 dose of vaccine; (n) = number of participants reporting yes for at least 1 day or no for all days.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Manufacturing</title>
            <description>Participants received one single 0.5mL manufacturing scale dose of 13vPnC coadministered with measles, mumps, and rubella vaccine (MMR) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Pilot</title>
            <description>Participants received one single 0.5mL pilot scale dose of 13vPnC coadministered with measles, mumps, and rubella vaccine (MMR) and 12 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-Specified Systemic Events (Toddler Series)</title>
          <description>Systemic events (fever ≥ 38 degrees Celsius [C] but ≤ 39 C, fever &gt;39 C but ≤ 40 C, fever &gt; 40 C), decreased appetite, irritability, increased sleep, decreased sleep, use of medication to prevent symptoms, and use of medication to treat symptoms) were collected using an electronic diary. Participants may be represented in more than 1 category.</description>
          <population>The safety population included all participants who received at least 1 dose of vaccine; (n) = number of participants reporting yes for at least 1 day or no for all days.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever ≥38°C but ≤39°C (n=114,114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0"/>
                    <measurement group_id="O2" value="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;39°C but ≤40°C (n=112,113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                    <measurement group_id="O2" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;40°C (n=112,113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite (n=115,117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.9"/>
                    <measurement group_id="O2" value="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (n=119,123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.3"/>
                    <measurement group_id="O2" value="44.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased sleep (n=114,119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4"/>
                    <measurement group_id="O2" value="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased sleep (n=116,117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8"/>
                    <measurement group_id="O2" value="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medication to treat symptoms (n=113,115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.7"/>
                    <measurement group_id="O2" value="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medication to prevent symptoms (n=114,114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3"/>
                    <measurement group_id="O2" value="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Antibody Concentration in 13vPnC Manufacturing Scale Group Relative to 13vPnC Pilot Scale Group After the 3-Dose Infant Series</title>
        <description>Antibody concentration/geometric mean concentration (GMC) as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
        <time_frame>One month after 3-dose infant series (5 months of age)</time_frame>
        <population>Evaluable immunogenicity (per protocol) population were participants who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Manufacturing</title>
            <description>Participants received one single 0.5mL manufacturing scale dose of 13vPnC coadministered with Infanrix hexa at 2, 3, 4 months (infant series) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Pilot</title>
            <description>Participants received one single 0.5mL pilot scale dose of 13vPnC coadministered with Infanrix hexa at 2, 3, 4 months (infant series) and 12 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Concentration in 13vPnC Manufacturing Scale Group Relative to 13vPnC Pilot Scale Group After the 3-Dose Infant Series</title>
          <description>Antibody concentration/geometric mean concentration (GMC) as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
          <population>Evaluable immunogenicity (per protocol) population were participants who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common Serotypes-Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.09" lower_limit="1.81" upper_limit="2.40"/>
                    <measurement group_id="O2" value="1.55" lower_limit="1.34" upper_limit="1.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80" lower_limit="0.65" upper_limit="0.98"/>
                    <measurement group_id="O2" value="0.83" lower_limit="0.66" upper_limit="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.28" lower_limit="1.13" upper_limit="1.43"/>
                    <measurement group_id="O2" value="1.21" lower_limit="1.08" upper_limit="1.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.15" lower_limit="1.77" upper_limit="2.61"/>
                    <measurement group_id="O2" value="2.30" lower_limit="1.91" upper_limit="2.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.60" lower_limit="1.38" upper_limit="1.87"/>
                    <measurement group_id="O2" value="1.51" lower_limit="1.31" upper_limit="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.60" lower_limit="1.40" upper_limit="1.83"/>
                    <measurement group_id="O2" value="1.64" lower_limit="1.44" upper_limit="1.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.82" lower_limit="0.69" upper_limit="0.98"/>
                    <measurement group_id="O2" value="0.92" lower_limit="0.77" upper_limit="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" lower_limit="1.21" upper_limit="1.66"/>
                    <measurement group_id="O2" value="1.29" lower_limit="1.10" upper_limit="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.20" lower_limit="1.05" upper_limit="1.38"/>
                    <measurement group_id="O2" value="1.21" lower_limit="1.06" upper_limit="1.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96" lower_limit="0.84" upper_limit="1.09"/>
                    <measurement group_id="O2" value="1.00" lower_limit="0.87" upper_limit="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87" lower_limit="0.74" upper_limit="1.03"/>
                    <measurement group_id="O2" value="1.05" lower_limit="0.89" upper_limit="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="1.77" upper_limit="2.25"/>
                    <measurement group_id="O2" value="2.14" lower_limit="1.89" upper_limit="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.19" lower_limit="1.91" upper_limit="2.50"/>
                    <measurement group_id="O2" value="2.31" lower_limit="2.05" upper_limit="2.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 4 the GMC ratio was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio</param_type>
            <param_value>1.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.10</ci_lower_limit>
            <ci_upper_limit>1.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 6B the GMC ratio was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 9V the GMC ratio was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 14 the GMC ratio was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 18C the GMC ratio was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 19F the GMC ratio was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 23F the GMC ratio was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 1 the GMC ratio was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio</param_type>
            <param_value>1.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 3 the GMC ratio was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 5 the GMC ratio was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 6A the GMC ratio was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 7F the GMC ratio was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 19A the GMC ratio was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>13vPnC Manufacturing Infant Series</title>
          <description>Participants received one single 0.5mL manufacturing scale dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with combined diphtheria, tetanus, and acellular pertussis inactivated poliovirus, and hemophilus influenza type b vaccine (DTaP-IPV-Hib) and hepatitis B virus vaccine (HBV) at 2 months (infant series, dose 1). Participants received one single 0.5mL manufacturing scale dose of 13vPnC coadministered with DTaP-IPV-Hib at 3 and 4 months (infant series, dose 2 and 3).</description>
        </group>
        <group group_id="E2">
          <title>13vPnC Pilot Infant Series</title>
          <description>Participants received one single 0.5mL pilot scale dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with combined diphtheria, tetanus, and acellular pertussis inactivated poliovirus, and hemophilus influenza type b vaccine (DTaP-IPV-Hib) and hepatitis B virus vaccine (HBV) at 2 months (infant series, dose 1). Participants received one single 0.5mL pilot scale dose of 13vPnC coadministered with DTaP-IPV-Hib at 3 and 4 months (infant series, dose 2 and 3).</description>
        </group>
        <group group_id="E3">
          <title>13vPnC Manufacturing Post-Infant Series</title>
          <description>Participants received one single 0.5mL manufacturing scale dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with combined diphtheria, tetanus, and acellular pertussis inactivated poliovirus, and hemophilus influenza type b vaccine (DTaP-IPV-Hib) and hepatitis B virus vaccine (HBV) at 2 months (infant series, dose 1). Participants received one single 0.5mL manufacturing scale dose of 13vPnC coadministered with DTaP-IPV-Hib at 3 and 4 months (infant series, dose 2 and 3). Assessment done at 5 months of age, 1 month after infant series.</description>
        </group>
        <group group_id="E4">
          <title>13vPnC Pilot Post-Infant Series</title>
          <description>Participants received one single 0.5mL pilot scale dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with combined diphtheria, tetanus, and acellular pertussis inactivated poliovirus, and hemophilus influenza type b vaccine (DTaP-IPV-Hib) and hepatitis B virus vaccine (HBV) at 2 months (infant series, dose 1). Participants received one single 0.5mL pilot scale dose of 13vPnC coadministered with DTaP-IPV-Hib at 3 and 4 months (infant series, dose 2 and 3). Assessment done at 5 months of age, 1 month after infant series.</description>
        </group>
        <group group_id="E5">
          <title>13vPnC Manufacturing Toddler Series</title>
          <description>Participants received one single 0.5mL manufacturing scale dose of 13vPnC coadministered with measles, mumps, and rubella vaccine (MMR) and 12 months of age (toddler dose).</description>
        </group>
        <group group_id="E6">
          <title>13vPnC Pilot Toddler Series</title>
          <description>Participants received one single 0.5mL pilot scale dose of 13vPnC coadministered with measles, mumps, and rubella vaccine (MMR) and 12 months of age (toddler dose).</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Pneumonia primary atypical</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Rotavirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Local reactions</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="48" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="55" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Hip dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Dacryostenosis congenital</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Plagiocephaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Dacryostenosis acquired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Enlarged uvula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Frequent bowel movements</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Infantile colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Infrequent bowel movements</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Teething</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever ≥38°C but ≤39°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="114"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever ≥38°C but ≤39°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever ≥38°C but ≤39°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 3 Infant Series</description>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="121"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;39°C but ≤40°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;39°C but ≤40°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;39°C but ≤40°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 3 Infant Series</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;40°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;40°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;40°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 3 Infant Series</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="115"/>
                <counts group_id="E6" subjects_affected="27" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 3 Infant Series</description>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="121"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="48" subjects_at_risk="119"/>
                <counts group_id="E6" subjects_affected="55" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 3 Infant Series</description>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Increased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="114"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Increased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Increased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 3 Infant Series</description>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="121"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="116"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 3 Infant Series</description>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Milk allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Exanthema subitum</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Corneal abrasion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rickets</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Posture abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Hypotonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Poor quality sleep</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Psychomotor retardation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Posthitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Tenderness (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="115"/>
                <counts group_id="E6" subjects_affected="34" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Tenderness (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Tenderness (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 3 Infant Series</description>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Tenderness (Significant)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Tenderness (Significant)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Tenderness (Significant)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 3 Infant Series</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Induration (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="30" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Induration (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Induration (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 3 Infant Serie</description>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Induration (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="29" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Induration (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Induration(Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 3 Infant Series</description>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="121"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Induration (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Induration (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Induration (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 3 Infant Series</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Induration (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Induration (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Induration (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 3 Infant Series</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Erythema (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="43" subjects_at_risk="115"/>
                <counts group_id="E6" subjects_affected="49" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Erythema (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Erythema (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 3 Infant Series</description>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Erythema (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="39" subjects_at_risk="115"/>
                <counts group_id="E6" subjects_affected="42" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Erythema (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Erythema (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 3 Infant Series</description>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Erythema (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Erythema (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Erythema (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 3 Infant Series</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Erythema (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Erythema (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Erythema (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 3 Infant Series</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>U. S. Contact Center</name_or_title>
      <organization>Wyeth</organization>
      <email>clintrialresults@wyeth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

